1. Researchers call out Gilead over diversity of remdesivir trials — Bristol-Myers commits $300M to combat racial disparities — Goldman predicts at least one coronavirus vaccine approval before the end of 2020 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Lawsuit: Judge bars Ex-Stryker employee from AAOS conference

Discussion in 'Blue Belt Technologies' started by Anonymous, Mar 22, 2013 at 1:07 AM.

  1. Anonymous

    Anonymous Guest

  2. Anonymous

    Anonymous Guest

    They are just h8ing on Blue Belt because they know its a blockbuster. Knees, wrists , ankles spines, skulls and then soft tissue to destroy even Intuitive Surgical. True innovation and no court or corporation can stop true innovation.
     
  3. Anonymous

    Anonymous Guest

    Bruty, is that you? If it is, we missed ya in Chi-town. The deep dish was delicious.
     
  4. Anonymous

    Anonymous Guest

    Rofl. Stryker could have bought BlueBelt for pocket change. Instead, they bought Mako for $1.6 BILLION. Maybe BB can cut a deal with Black & Decker and be on Home Depot shelves in time for Xmas.
     
  5. Anonymous

    Anonymous Guest

    Nothing great about this system. Several surgeons have mentioned the difficulty / impossible managing the posterior resection (told to wing it with a saw) AKA the flexion space to those non literate in orthopedics. This is a Navigation bur prompt up as Robotic for pure marketing purposes